With the biologics market a growing focus of development across the globe, what role does antitrust have to play in order to ensure healthy price competition between reference-priced biologics and competing biosimilars?

Hendrik Viaene speaks in this session which will focus on this role, and what lessons can and cannot be learned from generics, to help ensure low cost versions are available to all.

Moderator
David Giardina, Sidley Austin

Panel
Sheng Li, NERA Economic Consulting
Elaine Johnston, Allen & Overy
Hendrik Viaene, McDermott, Will & Emery

For more information, and to register, please click here.